Vebreltinib for glioblastoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 8 Oct 2018: Trial started, NCT06105619
  2. 27 Oct 2023: Trial registered, NCT06105619

The trials

NCT06105619: A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).

State
Under way
Phase
Phase 2 and Phase 3
People
84 taking part
Started
8 Oct 2018
Primary completion
1 Apr 2023
Arms
PLB1001
Results
None posted
  1. 8 Oct 2018: Trial started
  2. 27 Oct 2023: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as PLB1001.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.